IXICO Assets per Share
The Total Assets per Share of IXICO (IXI.L) as of Aug 10, 2026 is 0.15 GBP. In the previous year, Total Assets per Share was 0.13 GBP — a change of 23.70% (higher).
Get this data via API
Financial Data API
Assets per Share
0.15GBP
YoY
23.70%
Last updated:
Total Assets per Share of IXICO is 2026 0.15 GBP. Total Assets per Share of IXICO was 2025 0.13 GBP. It decreases by 23.70% higher compared to the previous year.
Access this data via the Eulerpool API
IXICO Stock analysis
What does IXICO do? IXICO PLC is a leading company in the field of digital biomarker and data services in clinical development. The company was originally founded in London in 2004 and has since had a successful history in neurology and psychiatry research. IXICO's core competency lies in developing and commercially implementing innovative solutions in the field of digital biomarker analysis, data capture, and processing. Through the use of advanced image analysis, structural analysis, and cognitive assessment technologies, IXICO enables effective clinical development of drugs and therapies, particularly in the areas of neurological and psychiatric disorders. IXICO is organized into three main divisions: Digital Healthcare Analytics (DHA), Data Analytics Services (DAS), and Clinical Trial Technology Solutions (CTTS). Each division includes its own products and services tailored to meet the specific requirements and needs of customers. The Digital Healthcare Analytics division focuses on developing biomarker-based clinical software-as-a-service (SaaS) solutions. These are used for monitoring and diagnosing neurological disorders such as Alzheimer's, Parkinson's, and schizophrenia. The solutions developed are tailored to the needs of clinics, research institutions, and biopharmaceutical companies and significantly contribute to the improvement of patient analysis and treatment. The Data Analytics Services division includes a wide range of services for data capture, processing, and analysis. This includes, for example, image and data analysis of clinical data, support for sponsors in data management and study monitoring, as well as consulting and training services. The purpose of this division is to help sponsors work in compliance with regulatory requirements and best practices in the pharmaceutical industry. IXICO's Clinical Trial Technology Solutions division offers a range of technology solutions to support the clinical research of pharmaceutical and biotechnology companies. This includes software solutions such as Neurostatus.net, a neurostatus toolkit for digital assessment of neurological patients, and TrialTracker, a SaaS solution that supports sponsors in the planning and conduct of studies. With its pioneering products and services, IXICO has numerous customers worldwide, including large pharmaceutical and biotech companies. The company also has partnerships with some of the most renowned academic institutions in Europe and North America and is proud to have been part of some of the most significant clinical studies in the field of neurology in recent years. Under the leadership of founder and CEO Derek Hill, IXICO has built an experienced and highly qualified team of scientists and industry experts over the years. The employees come from a variety of disciplines and industries and work closely together to develop innovative solutions and meet customer needs. The company expects to continue successfully focusing on the development of technology-based solutions in clinical research in the future. IXICO is one of the most popular companies on Eulerpool.
Frequently Asked Questions about IXICO stock
Total Assets per Share of IXICO is 0.15 GBP in 2026.
Total Assets per Share of IXICO changed from 0.13 GBP to 0.15 GBP, representing a 23.70% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Total Assets per Share IXICO since 2006 – with annual values, charts, and detailed analysis.
Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.
Access this data via the Eulerpool API
Other — IXICO
All Key Metrics — IXICO
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth